RU2009113557A - Фармацевтические композиции для перорального или ректального введения белковых веществ - Google Patents

Фармацевтические композиции для перорального или ректального введения белковых веществ Download PDF

Info

Publication number
RU2009113557A
RU2009113557A RU2009113557/15A RU2009113557A RU2009113557A RU 2009113557 A RU2009113557 A RU 2009113557A RU 2009113557/15 A RU2009113557/15 A RU 2009113557/15A RU 2009113557 A RU2009113557 A RU 2009113557A RU 2009113557 A RU2009113557 A RU 2009113557A
Authority
RU
Russia
Prior art keywords
substances
active agents
composition according
tnfα
cytokines
Prior art date
Application number
RU2009113557/15A
Other languages
English (en)
Russian (ru)
Inventor
Мауро АЯНИ (IT)
Мауро АЯНИ
Луиджи МОРО (IT)
Луиджи МОРО
Роберто ВИЛЛА (IT)
Роберто ВИЛЛА
Original Assignee
Космо Текнолоджиз Лтд (Ie)
Космо Текнолоджиз Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI20061741 external-priority patent/ITMI20061741A1/it
Priority claimed from ITMI20071205 external-priority patent/ITMI20071205A1/it
Application filed by Космо Текнолоджиз Лтд (Ie), Космо Текнолоджиз Лтд filed Critical Космо Текнолоджиз Лтд (Ie)
Publication of RU2009113557A publication Critical patent/RU2009113557A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2009113557/15A 2006-09-12 2007-09-07 Фармацевтические композиции для перорального или ректального введения белковых веществ RU2009113557A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI20061741 ITMI20061741A1 (it) 2006-09-12 2006-09-12 Composizioni farmaceutiche per la somministrazione orale di sostanze proteiche
ITMI2006A001741 2006-09-12
ITMI2007A001205 2007-06-15
ITMI20071205 ITMI20071205A1 (it) 2007-06-15 2007-06-15 Composizioni farmaceutiche per la somministrazione orale o rettale di sostanze proteiche

Publications (1)

Publication Number Publication Date
RU2009113557A true RU2009113557A (ru) 2010-10-20

Family

ID=39107203

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009113557/15A RU2009113557A (ru) 2006-09-12 2007-09-07 Фармацевтические композиции для перорального или ректального введения белковых веществ

Country Status (8)

Country Link
US (1) US20100004157A1 (https=)
EP (1) EP2081555A2 (https=)
JP (1) JP2010502759A (https=)
KR (1) KR20090086060A (https=)
CA (1) CA2663548A1 (https=)
MX (1) MX2009002756A (https=)
RU (1) RU2009113557A (https=)
WO (1) WO2008031770A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12203056B2 (en) 2008-03-28 2025-01-21 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
US8809392B2 (en) 2008-03-28 2014-08-19 Ecolab Usa Inc. Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents
GB201017048D0 (en) * 2010-10-08 2010-11-24 Ucl Business Plc Composition
US10946091B2 (en) * 2012-06-04 2021-03-16 Gaurav Agrawal Compositions and methods for treating Crohn's disease and related conditions and infections
US10220076B2 (en) * 2014-05-15 2019-03-05 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising glucose regulating proteins
US11548940B2 (en) 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10689460B2 (en) 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
CN113546036A (zh) * 2015-05-01 2021-10-26 拉尼医疗有限公司 药物组合物和用于制备包含多肽和/或蛋白质的固体块的方法
EP3294273A4 (en) * 2015-05-08 2018-12-05 Incube Labs, LLC Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
SG11201807402PA (en) * 2016-03-31 2018-09-27 Vhsquared Ltd Compositions
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
EP3554541B1 (en) * 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3501503A1 (en) 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
US12559552B2 (en) 2019-06-21 2026-02-24 Sorriso Pharmaceuticals, Inc. IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
JPH10503179A (ja) * 1994-06-24 1998-03-24 イミュネックス・コーポレーション 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法
CA2377301C (en) * 1999-06-14 2009-05-12 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
EP1487457A1 (en) * 2001-11-30 2004-12-22 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
ITMI20012599A1 (it) * 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
US8389008B2 (en) * 2003-09-19 2013-03-05 Penwest Pharmaceuticals Co. Delayed release dosage forms
EP2422804A1 (en) * 2004-06-17 2012-02-29 Amano Enzyme USA., Ltd. Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers
US7879361B2 (en) * 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
UA95235C2 (en) * 2005-05-04 2011-07-25 Зииланд Фарма А/С Glucagon-like-peptide-2 (glp-2) analogues

Also Published As

Publication number Publication date
CA2663548A1 (en) 2008-03-20
US20100004157A1 (en) 2010-01-07
KR20090086060A (ko) 2009-08-10
WO2008031770A2 (en) 2008-03-20
JP2010502759A (ja) 2010-01-28
MX2009002756A (es) 2009-05-25
EP2081555A2 (en) 2009-07-29
WO2008031770A3 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
RU2009113557A (ru) Фармацевтические композиции для перорального или ректального введения белковых веществ
JP2010502759A5 (https=)
CN109152738B (zh) 组合物
JP2022141701A (ja) ブルトン型チロシンキナーゼ阻害剤の薬学的製剤
Shashank et al. Approaches to increase the gastric residence time: floating drug delivery systems-a review
CN108653272B (zh) 青蒿素类衍生物在制备用于治疗炎症性肠病的药物中的用途
JP5926243B2 (ja) 経口薬物療法のための方法および組成物
BR112019018576A2 (pt) métodos de tratamento de doença de crohn e colite ulcerativa
TW200800265A (en) Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
JP2019529476A5 (https=)
WO2014190898A1 (zh) 一种异硫氰酸酯类化合物制剂
KR20230046307A (ko) 신규 위체류 연장 방출 투여 형태
KR102699072B1 (ko) 항체 및 이의 단편을 사용한 염증성 장 질환의 국소 치료
CN109803684A (zh) 用于治疗肝细胞癌的组合疗法
ES2681195T3 (es) Utilización de la proteína de fusión TACI-Ig, tal como atacicept, para la fabricación de un medicamento para el tratamiento de lupus eritematoso
ES2870562T3 (es) Composiciones y procedimientos para el tratamiento del crecimiento celular anormal
ES3060895T3 (en) Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
Dubey et al. Advancements and Challenges in Gastroretentive Drug Delivery Systems: A Comprehensive Review of Research Innovation, Technologies, and Clinical Applications
Bhandwalkar et al. Review on gastroretentive drug delivery system
JP7372740B2 (ja) 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ
BR112021010516A2 (pt) Tratamento tópico de diarreia, colite ou enterocolite induzida por inibidor de ponto de verificação imunológico usando anticorpos e fragmentos dos mesmos
KR20250123210A (ko) Her2 억제제 고체 분산체의 투여 스케줄
CN101534800A (zh) 用于口服或直肠施用蛋白质物质的药物组合物
Xu et al. Tenosynovial giant cell tumor (TGCT): mechanisms and advances in targeted treatments
Mojsilović et al. A Thirty-Seven-Year Follow-Up of Peutz–Jeghers Syndrome across Three Generations

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20110927